Hypertension and Heart Failure Unit, Department of Cardiology, Hôpital Brabois, CHU de Nancy, Nancy, F-54000, France.
Heart Fail Rev. 2010 Jul;15(4):319-29. doi: 10.1007/s10741-009-9143-0.
Given the importance of fibrous tissue in leading to myocardial dysfunction, non-invasive assessment of fibrosis could prove a clinically useful tool in heart failure (HF) patients. Biomarkers may be used for early detection of otherwise subclinical disease, diagnostic assessment of an acute or chronic clinical syndrome, risk stratification of patients with a suspected or confirmed diagnosis, selection of an appropriate therapeutic intervention and monitoring the response to therapy. Extracellular matrix (ECM) biomarkers in HF are promising biomarkers. They are able to detect early changes in heart and large vessel structure and function and transition to HF. High ECM biomarker levels have been associated with poor outcome. The ability of treatment to reduce myocardial fibrosis in HF patients may be monitored by the measurement of various serum peptides arising from the metabolism of collagen types. Biomarkers may be selectively influenced by pharmacological agents.
鉴于纤维组织在导致心肌功能障碍方面的重要性，非侵入性纤维化评估可能成为心力衰竭（HF）患者的一种临床有用工具。生物标志物可用于早期发现亚临床疾病，对急性或慢性临床综合征进行诊断评估，对疑似或确诊患者进行风险分层，选择适当的治疗干预措施，并监测治疗反应。HF 中的细胞外基质（ECM）生物标志物是很有前途的生物标志物。它们能够检测心脏和大血管结构和功能的早期变化，并向 HF 转变。高 ECM 生物标志物水平与不良预后相关。通过测量源自胶原类型代谢的各种血清肽，可监测 HF 患者治疗减少心肌纤维化的能力。生物标志物可能会受到药物的选择性影响。
